期刊文献+

多西他赛体外干预前列腺癌PC-3细胞转移能力的实验研究 被引量:5

Effect of docetaxel on invasion and matestasis of prostate cancer PC-3 cell line
下载PDF
导出
摘要 目的:研究不同浓度多西他赛体外对人前列腺癌PC-3细胞侵袭力及MMP-2、MMP-9表达水平的影响。方法:在0.1血浆峰值浓度(peakplasma concentration,PPC)、1.0PPC、10.0PPC的多西他赛作用下,用Transwell小室对前列腺癌PC-3细胞的侵袭力与转移能力进行检测,并采用荧光定量RT-PCR方法检测转移相关水解蛋白酶MMP-2和MMP-9的变化。结果:经0.1PPC、1.0PPC和10.0PPC的多西他赛处理后,在1.0PPC和10.0PPC下,人前列腺癌PC-3细胞趋化、侵袭能力均下调,而0.1PPC浓度下,人前列腺癌PC-3细胞趋化能力变化不大,而侵袭能力明显降低。在各处理组PC-3细胞中,0.1PPC、1.0PPC和10.0PPC组的MMP-2mRNA的表达水平分别为0.40±0.12、0.36±0.16和0.26±0.09,MMP-9mRNA的表达水平分别为0.35±0.10、0.31±0.12和0.19±0.08,均显著低于两者相应的空白对照组,提示MMP-2和MMP-9转录水平明显降低。结论:多西他赛能够通过下调MMP-2和MMP-9基因的转录而抑制人前列腺癌PC-3细胞的侵袭力。 OBJECTIVE: To investigate the effect of docetaxel on the invasion and expression of MMP-2 and MMP-9 of prostate cancer PC-3 cell line. METHODS: PC-3 cell line was treated with three concentrations of docetaxel as fellow: 0.1,1.0,10.0 PPC. The invasion and chemiotaxis of PC-3 cell line were detected by the matrigel and Transwell assay, respectively. MMP-2 and MMP-9 mRNA levels in PC-3 cell line were measured by real-time quantitative RT-PCR. RESULTS: At the concentrations of 1.0, 10. 0 PPC,the ability of invasion and chemiotaxis were inhibited, but at the concentration of 0. 1 PPC, docetaxel suppressed the invasion of PC-3 cell line, and did not decrease chemiotaxis. After the treatment of docetaxel, the expressions of MMP-2 mRNA were 0. 40 + 0. 12,0.36 ± 0. 16,0. 26 ± 0. 09, and MMP-9 mRNA levels were 0. 35±0. 10,0. 31±0. 12,0.19±0. 08, respectively. The expressions of MMP-2 mRNA and MMP-9 mRNA decreased significantly in the defferent concentrations of 0. 1PPC, 1.0 PPC and 10. 0 PPC. CONCLUSION: Docetaxel can inhibit the invasion of PC-3 cell line via down-regulation of MMP-2 and MMP-9 mRNA levels.
出处 《中华肿瘤防治杂志》 CAS 2007年第21期1620-1622,共3页 Chinese Journal of Cancer Prevention and Treatment
基金 广西科学青年基金(0640061)
关键词 前列腺肿瘤/药物疗法 肿瘤 实验性/药物疗法 紫杉烷类/治疗应用 prostatic neoplasms/drug therapy neoplasms, experimental/drug therapy taxoids/therapeutic use
  • 相关文献

参考文献7

二级参考文献30

  • 1刘龙,刘璐,童冠圣,封国生,高宏,高文,李澄,刘志勇.^(32)P-磷酸铬体外诱导人非小细胞肺癌A549细胞凋亡[J].中华放射医学与防护杂志,2004,24(3):233-236. 被引量:2
  • 2王涛,江泽飞,宋三泰,张少华,申戈,于静新.单药希罗达治疗复发转移性乳腺癌的疗效观察[J].中华肿瘤杂志,2004,26(6):379-381. 被引量:57
  • 3Small EJ, Reese DM, Vogelzang NJ. Hormone - refractory prostate cancer:an evolving standard of care. Semin Oncol, 1999,26( 5 suppl 17):6767.
  • 4Khan MA, Carducci MA, Partin AW, et al. The evolving role of docetaxel in the management of androgen independent prostate cancer. J Urol,2003,170(5) :1709 - 16.
  • 5Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med,2004,351 (15): 1502 - 12.
  • 6Petrylak DP, Tangen CM, Hussain MH, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med,2004,351 (15): 1513 - 20.
  • 7Walczak JR, Carducci MA. Eastern Cooperative Oncology Group E1899.Phase 3 randomized trial evaluating second- line hormonal therapy versus docetaxel- estramustine combination chemotherapy on progression- free survival in asymptomatic patients with a rising prostate - specific antigen level after hormonal therapy for prostate cancer: an Eastern Cooperative Oncology Group(E1899), Intergroup/Clinical Trials Support Unit study.Urology,2003,62 Suppl 1:141-6.
  • 8Beer TM, Eilers KM, Garzotto M, et al. Quality of life and pain relief during treatment with calcitriol and docetaxel in symptomatic metastatic androgen - independent prostate carcinoma. Cancer, 2004, 100 (4): 758 -63.
  • 9Dahut WL, Gulley JL, Arlen PM, et al. Randomized phase Ⅱ trial of docetaxel plus thalidomide in androgen - independent prostate cancer. J Clin Oncol, 2004,22(13) :2532 - 9.
  • 10Vordos D, Paule B, Vacherot F, et al. Docetaxel and zoledronic acid in patients with metastatie hormone- refractory prostate cancer. BJU Int,2004,94(4) :524 - 7.

共引文献18

同被引文献39

  • 1邹自灏,刘平,李育斌,钟剑峰,黄伟佳,潘兆君.多西他赛联合泼尼松治疗激素难治性前列腺癌的近期疗效[J].中国老年学杂志,2014,34(7):1792-1793. 被引量:3
  • 2叶定伟,张海梁,姚旭东,张世林,戴波,沈益君,朱耀,朱一平,陈羽,夏峥嵘.多西他赛联合泼尼松或米托蒽醌联合泼尼松治疗激素抵抗性前列腺癌[J].中国癌症杂志,2007,17(3):236-239. 被引量:19
  • 3孙忠全,钱伟庆,宋建达.多西他赛联合泼尼松治疗激素难治性前列腺癌[J].老年医学与保健,2007,13(3):155-157. 被引量:6
  • 4Vaishampayan U, Hussain M. Update in systemic therapy of prostate cancer: improvement in quality and duration of life. Expert Rev Anticancer Ther, 2008; 8(2):269-281.
  • 5那彦群,叶章群,孙光.中国泌尿外科疾病诊断治疗指南[M].1版.北京:人民卫生出版社,2011,129.
  • 6Cheetham PJ,Petrylak DP. Alpha particles as radiopharmaceuti- cals in the treatment of bone metastases: mechanism of action of radium-223 chloride (Alpharadin) and radiation protection[J]. Oncol (Williston Park) ,2012,26(4) :330-337,341.
  • 7Tannoek IF, de Wit R, Berry WR, et al. Docetaxel plus predni- sone or mitoxantrone plus prednisone for advanced prostate cane- er[J]. N Engl J Med,2004,351(15) :1502-1512.
  • 8Berthold DR,Pond GR,Soban F,et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study[J]. J Clin Oneol, 2008,26 (2) :242-245.
  • 9Suzuki K. Prostate cancer-the role of docetaxel on castration-re- sistant prostate cancer: evaluation of efficacy and subsequent treatment[J]. Gan To Kagaku Ryoho, 2012,39(10) : 1467-1470.
  • 10Kubler H, Miller K. New therapy concepts for castration-resist- ant prostate cancer: Between hormone manipulation, targeted therapy and chemotherapy[J]. Urologe A, 2013,52 ( 11 ) : 1517- 1528.

引证文献5

二级引证文献27

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部